ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,767.50
0.10%
S&P ASX All Technology
3,137.90
0.55%
Brent Oil
84.85
0.00%
US Dollar vs AUD
1.49566
0.00%
Bitcoin
60,903.45
0.98%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Mural Oncology PLC (MURA) Share Price

Mural Oncology PLC

Mural Oncology PLC (MURA)

NASDAQ
0.00
0.00
(0.00%)
Closed 30 June 6:00AM
Delayed by 15 minutes
0.00
0.00
(0.00%)
After Hours: -
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
-
Bid
-
Offer
-
Volume
-
0.00 Day's Range 0.00
3.03 52 Week Range 17.00
Previous Close
-
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
160,494
Financial Volume
-
VWAP
-

MURA Latest News

More News

Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference

WALTHAM, Mass. and DUBLIN, June 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...

06 June 2024
GlobeNewswire Inc.

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass. and DUBLIN, June 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...

05 June 2024
GlobeNewswire Inc.

Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting

ARTISTRY-3 trial is being conducted to evaluate less frequent dosing of nemvaleukin alfa, Mural’s late-stage lead candidate Nemvaleukin demonstrated pharmacodynamic proof of mechanism in...

24 May 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

14 May 2024
Edgar (US Regulatory)

Form 8-K - Current report

14 May 2024
Edgar (US Regulatory)

Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update

Mural’s lead product candidate, nemvaleukin alfa, is in two potentially registrational trials in platinum resistant ovarian cancer and mucosal melanoma, both of which are on track with readouts...

14 May 2024
GlobeNewswire Inc.

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass and DUBLIN, May 03, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation...

04 May 2024
GlobeNewswire Inc.

Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

WALTHAM, Mass. and DUBLIN, Ireland, April 24, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered...

25 April 2024
GlobeNewswire Inc.
Period †ChangeChange %OpenHighLowAvg. Daily VolVWAP
1003.233.293.032577553.15840383CS
4003.393.513.031780173.25574308CS
12004.744.743.031604943.63445763CS
26005.546.24993.032290524.54880255CS
520016.69173.033916044.27108241CS
1560016.69173.033916044.27108241CS
2600016.69173.033916044.27108241CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LDROLode Resources Ltd
AUD 0.005
(400.00%)
49.26k
TKMOTrek Metals Limited
AUD 0.002
(100.00%)
277.78k
IBGOIronbark Zinc Limited
AUD 0.002
(100.00%)
1.25M
BFCBeston Global Food Company Limited
AUD 0.003
(50.00%)
8.94M
TD1Tali Digital Limited
AUD 0.0015
(50.00%)
1.05M
RAGORagnar Metals Limited
AUD 0.001
(-75.00%)
1M
ACMOAAustralian Critical Minerals Ltd
AUD 0.013
(-56.67%)
45k
AEVOAvenira Limited
AUD 0.001
(-50.00%)
3M
GRLOGodolphin Resources Limited
AUD 0.001
(-50.00%)
3M
HYTOHyTerra Ltd
AUD 0.011
(-35.29%)
1.2M
PENPeninsula Energy Ltd
AUD 0.1025
(0.00%)
77.12M
SYASayona Mining Limited
AUD 0.036
(-2.70%)
59.44M
ADNAndromeda Metals Limited
AUD 0.016
(-11.11%)
49.06M
IMUImugene Limited
AUD 0.057
(5.56%)
45.01M
SGRStar Entertainment Group Limited
AUD 0.50
(2.56%)
40.45M

Discussion

View Full Feed
zab zab 4 minutes ago
You like weak and stupid, someone who surrenders easily. Trump fits your personality, being afraid.
Jlinvest01 Jlinvest01 4 minutes ago
Interest rates are the same forall. Higher cost of refinancing shouldn't matter if trajectory to break even is clear. Company is trading at less than 1x forward sales and about 1x this year sales. Whether they pull break even in 25 or 26 shouldn't matter. Daxy will be the best Bont out there for at
RVNC
theorysuit theorysuit 5 minutes ago
Journal article to explain their trial results Means guaranteed approval. Again Noted!
NWBO
JTORENCE JTORENCE 5 minutes ago
GrannPiano NOPE-You must be a newbee share holder.
NWBO
totffe totffe 5 minutes ago
Me, too. If one sneers at charts on the OTC then they should become a gardner.
EMGE
Real McCoy Real McCoy 5 minutes ago
Off topic
jour_trader jour_trader 6 minutes ago
I’m missing something. You don’t record accounts receivable without recording revenue. It’s impossible from an accounting standpoint.
ELTP
rooster rooster 6 minutes ago
I don’t have any problems with him
glenn1919 glenn1919 6 minutes ago
IMUX......BIOL......RDZN......POET.....................https://stockcharts.com/h-sc/ui?s=POET&p=D&yr=0&mn=3&dy=0&id=p11960084343
https://stockcharts.com/h-sc/ui?s=RDZN&p=D&yr=0&mn=3&dy=0&id=p11960084343
https://stockcharts.com/h-sc/ui?s=BIOL&p=D&yr=0&mn=3&dy=0&id=p11960084343
ht
RDZN
beartrap12 beartrap12 7 minutes ago
ASM begins at 1:30 Eastern Time.
ASM
totffe totffe 7 minutes ago
I blocked that fool a long time ago. This is one of the best plays on the OTC. Recent trading activity points to a break out on the horizon. Get 'em while you can.
GRST
Timing101 Timing101 7 minutes ago
$DUTV Well I got a response on my challenge , from a Mark G close supporter answering they thought my challenge I put out to Mark G, "check out the Message from Mark G today 6.29.24" so I did. OMG, the SAME MESSAGE at the SAME LOCATION it appears like one landing down , no names, no details
CSOL DUTV
flipper44 flipper44 7 minutes ago
“All we will here”. — ex

“Three” — ex

There were seven.

At least we know it’s you.
NWBO
cottonmather cottonmather 7 minutes ago
Jim Rickards. Pop goes the weasel. 12 minutes https://youtu.be/-_v98xm9iX8?si=8VVoirztqBsQfQQ0
Trend-Setter Trend-Setter 8 minutes ago
Oh wow! You just made my prediction too low but wholeheartedly accept if I'm wrong and looking forward to your analysis being proven right. Kudos to you sir!
ELTP
prototype_101 prototype_101 8 minutes ago
Infinera: Optics is Everywhere in the AI Era

Interview from OFC 2024, Heavy Reading analyst Sterling Perrin and Infinera CEO David Heard discuss how the AI traffic boom will drive optics in data center interconnect, subsea and terrestrial telecom networks, and also open new opportunit
LWLG
nickypicky nickypicky 8 minutes ago
There is a lack of real market makers here like crypto which brings big swings when size shows up to buy or sell in my opinion.
MARA
zab zab 9 minutes ago
Republicans have not addressed their problems with trump
boston745 boston745 10 minutes ago
Notice that on April 1st, L1 filed its 13G indicating it had 8.8% of outstanding stock. Two days later, Sintx announces an offering at 2.1 cents adding 71m shares of stock.
(2) Based on 51,080,139 shares of Common Stock outstanding as reported in the Issuer’s filings with the Securities and
SINT
gyro 1 gyro 1 10 minutes ago
Well said Matrix55. Further of interest might be a business chance coming down the pike from Skyworks. Spinning off assets to Groen for development.
PonkenPlonken PonkenPlonken 11 minutes ago
Somethings very right here. Looking for 5+
ADCT
Squirrely_McShitty Squirrely_McShitty 11 minutes ago
moanathon?
CNNA
XMaster2023 XMaster2023 12 minutes ago
According to the 73 coauthors (mostly Doctors and other specialists with advanced degrees) the trial achieved statistical significance. DCVax-L was submitted to MHRA about 6 months ago on a 150 day accelerated approval process. Approval is near and you are full of it.
NWBO
theorysuit theorysuit 13 minutes ago
Keep replying with your BS pumper.


It is perfectly normal for the pre revenue bio to fund an external cdmo to the tune of $50m plus and the ceo to own it. Noted! And said ceo negotiates revenue with said cdmo. Again noted! Perfectly normal!

These are govern
NWBO
wisetoit wisetoit 13 minutes ago
Yes, stuck here with the rest of ya’ll…better than dealing with Hippy Trades…lol
FONU

Your Recent History

NASDAQ
MURA
Mural Oncology
BIT
CANA
UBS LUX FUND SOLUTIONS -...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved